Wellington Management Group LLP Boosts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Wellington Management Group LLP raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,659,007 shares of the biopharmaceutical company's stock after purchasing an additional 1,058,331 shares during the period. Gilead Sciences accounts for approximately 0.6% of Wellington Management Group LLP's investment portfolio, making the stock its 29th biggest holding. Wellington Management Group LLP owned about 2.86% of Gilead Sciences worth $3,293,822,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GILD. Bellevue Group AG grew its position in Gilead Sciences by 18.2% during the 3rd quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company's stock worth $3,859,000 after purchasing an additional 7,093 shares during the last quarter. Quantinno Capital Management LP lifted its stake in shares of Gilead Sciences by 149.5% during the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company's stock worth $6,843,000 after buying an additional 48,910 shares during the period. McAdam LLC grew its holdings in shares of Gilead Sciences by 16.7% during the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company's stock valued at $2,344,000 after buying an additional 3,627 shares during the last quarter. Capital Investment Advisors LLC increased its position in shares of Gilead Sciences by 2.6% in the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company's stock valued at $35,793,000 after acquiring an additional 9,791 shares during the period. Finally, Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its stake in Gilead Sciences by 3.9% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 142,167 shares of the biopharmaceutical company's stock worth $13,132,000 after acquiring an additional 5,382 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Remove Ads

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares of the company's stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last quarter, insiders sold 302,785 shares of company stock valued at $30,503,250. Corporate insiders own 0.16% of the company's stock.

Gilead Sciences Price Performance

NASDAQ:GILD traded down $0.77 during trading hours on Tuesday, hitting $111.28. 6,284,006 shares of the stock were exchanged, compared to its average volume of 7,301,817. The company has a market cap of $138.58 billion, a P/E ratio of 300.76, a P/E/G ratio of 0.71 and a beta of 0.21. The firm's fifty day moving average price is $106.25 and its 200 day moving average price is $95.40. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were given a dividend of $0.79 per share. The ex-dividend date was Friday, March 14th. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. Gilead Sciences's payout ratio is presently 854.05%.

Analysts Set New Price Targets

Several research firms have weighed in on GILD. JPMorgan Chase & Co. boosted their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday, February 12th. Wells Fargo & Company raised their price target on shares of Gilead Sciences from $120.00 to $140.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. The Goldman Sachs Group lifted their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a research note on Thursday, February 13th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.